Discoidin domain receptor 2 signaling networks and therapy in lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 6, 2014, Pages 900-904

  Payne, Leo S ^a   Huang, Paul H ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Collagen; Discoidin domain receptors; Kinase inhibitors; Lung cancer; Signal transduction

Indexed keywords

ALKALOID; DACTINOMYCIN; DASATINIB; DISCOIDIN DOMAIN RECEPTOR 2; DISCOIPYRROLE A; DISCOIPYRROLE D; ERLOTINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; DISCOIDIN RECEPTOR; LECTIN RECEPTOR;

ARTICLE; CANCER RESISTANCE; CANCER THERAPY; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; HUMAN; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; CARCINOMA, SQUAMOUS CELL; GENETICS; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY;

CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, MITOGEN; SIGNAL TRANSDUCTION;

EID: 84901436850     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000164     Document Type: Article

References (51)

1. Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012;18:2443-2451.
2. Drilon A, Rekhtman N, Ladanyi M, Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 2012;13:e418-e426.
3. Schiller JH, Harrington D, Belani CP, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non- small-cell lung cancer. N Engl J Med 2002; 346:92-98. (Pubitemid 34438899)
4. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22: 2184-2191. (Pubitemid 41095154)
5. Hainsworth JD, Fang L, Huang JE, et al. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first- line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol 2011;6:109-114.
6. Fidler MJ, Shersher DD, Borgia JA, Bonomi P. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol 2012;4:51-60.
7. Hammerman PS, Hayes DN, Wilkerson MD, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-525.
8. Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011;1:78-89.
9. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011;17:2081-2086.
10. An SJ, Chen ZH, Su J, et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 2012;7:e40109.
11. Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao MS, Vogel WF. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non- small cell lung carcinoma. Br J Cancer 2007;96:808-814. (Pubitemid 46380188)
12. Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005;65:7591-7595. (Pubitemid 41297230)
13. Consortium TCGA. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-525.
14. Sasaki H, Shitara M, Yokota K, et al. DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients. Oncol Lett 2012;4: 33-37.
15. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150:1107-1120.
16. Fu HL, Valiathan RR, Arkwright R, et al. Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. J Biol Chem 2013;288:7430-7437.
17. Day E, Waters B, Spiegel K, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008;599:44-53.
18. Pitini V, Arrigo C, Di Mirto C, Mondello P, Altavilla G. Response to dasatinib in a patient with SQCC of the lung harboring a discoid- receptor-2 and synchronous chronic myelogenous leukemia. Lung Cancer 2013;82:171-172.
19. Riess JW, Neal JW. Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer. J Thorac Oncol 2012;7(16 Suppl 5):S385-S386.
20. Borza CM, Pozzi A. Discoidin domain receptors in disease. Matrix Biol 2013. December 19, 2013 [E-pub Ahead of Print].
21. Valiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev 2012; 31: 295-321.
22. Iwai LK, Chang F, Huang PH. Phosphoproteomic analysis identifies insulin enhancement of discoidin domain receptor 2 phosphorylation. Cell Adh Migr 2013;7:161-164.
23. Xu H, Bihan D, Chang F, Huang PH, Farndale RW, Leitinger B. Discoidin domain receptors promote α1β1- and α2β1-integrin mediated cell adhesion to collagen by enhancing integrin activation. PLoS One 2012;7:e52209.
24. Ruiz PA, Jarai G. Collagen I induces discoidin domain receptor (DDR) 1 expression through DDR2 and a JAK2-ERK1/2-mediated mechanism in primary human lung fibroblasts. J Biol Chem 2011;286:12912-12923.
25. Xu AM, Huang PH. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res 2010;70:3857-3860.
26. Iwai LK, Payne LS, Luczynski MT, et al. Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild- type DDR2 and its lung cancer mutants. Biochem J 2013;454:501-513.
27. Guha U, Chaerkady R, Marimuthu A, et al. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A 2008;105:14112-14117.
28. Guo A, Villén J, Kornhauser J, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 2008; 105:692-697. (Pubitemid 351171770)
29. Wall SJ, Werner E, Werb Z, DeClerck YA. Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen. J Biol Chem 2005;280:40187-40194. (Pubitemid 41779155)
30. Henriet P, Zhong ZD, Brooks PC, Weinberg KI, DeClerck YA. Contact with fibrillar collagen inhibits melanoma cell proliferation by up- regulating p27KIP1. Proc Natl Acad Sci U S A 2000;97: 10026-10031.
31. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003;114:33-45. (Pubitemid 36859839)
32. White DE, Kurpios NA, Zuo D, et al. Targeted disruption of beta1- integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004;6:159-170. (Pubitemid 39485688)
33. Moran-Jones K, Ledger A, Naylor MJ. β1 integrin deletion enhances progression of prostate cancer in the TRAMP mouse model. Sci Rep 2012;2:526.
34. Huang PH. Phosphoproteomic studies of receptor tyrosine kinases: future perspectives. Mol Biosyst 2012;8:1100-1107.
35. Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009;15:35-44.
36. Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol 2010; 22:697-706.
37. Kwon MC, Berns A. Mouse models for lung cancer. Mol Oncol 2013;7:165-177.
38. Zhang S, Bu X, Zhao H, et al. A host deficiency of discoidin domain receptor 2 (DDR2) inhibits both tumor angiogenesis and metastasis. J Pathol 2013;232:436-448.
39. Badiola I, Olaso E, Crende O, Friedman SL, Vidal-Vanaclocha F. Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. Gut 2012;61:1465-1472.
40. Beauchamp EM, Woods BA, Dulak AM, et al. Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss. Mol Cancer Ther 2014;13:475-482.
41. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-2075. (Pubitemid 351439466)
42. Siddiqui K, Kim GW, Lee DH, et al. Actinomycin D identified as an inhibitor of discoidin domain receptor 2 interaction with collagen through an insect cell based screening of a drug compound library. Biol Pharm Bull 2009;32:136-141.
43. Hu Y, Potts MB, Colosimo D, et al. Discoipyrroles A-D: isolation, structure determination, and synthesis of potent migration inhibitors from Bacillus hunanensis. J Am Chem Soc 2013;135:13387-13392.
44. Potts MB, Kim HS, Fisher KW, et al. Using functional signature ontology (FUSION) to identify mechanisms of action for natural products. Sci Signal 2013;6:ra90.
45. Kim HG, Tan L, Weisberg EL, et al. Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor. ACS Chem Biol 2013;8:2145-2150.
46. Brunner AM, Costa DB, Heist RS, et al. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol 2013;8:1434-1437.
47. Rix U, Hantschel O, Dürnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055-4063. (Pubitemid 350248462)
48. Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25:1035-1044. (Pubitemid 47517638)
49. Haupt A, Joberty G, Bantscheff M, et al. Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics. BMC Cancer 2012;12:38.
50. Chen Z, Sasaki T, Tan X, et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 2010;70:9827-9836.
51. Sawai A, Chandarlapaty S, Greulich H, et al. Inhibition of Hsp90 down- regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 2008;68:589-596. (Pubitemid 351380088)